Acorai, a Helsingborg, Sweden-based company which specialized in cardiovascular health technology, received an investment from CerraCap Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to boost the development and deployment of its novel Acorai Heart Monitor (AHM), which aims to solve critical challenges in heart failure management.
Led by CEO Filip Peters, Acorai is developing a non-invasive intracardiac pressure monitoring device to improve heart failure management for more than 64 million patients worldwide. Its monitoring system is focused on heart failure monitoring, due to its accuracy and reliability in measuring the intracardiac pressures non-invasively. The device can provide precise data on important parameters such as pulmonary artery pressure (PAP), right atrial pressure (RAP), and pulmonary capillary wedge pressure (PCWP), which are crucial parameters to effectively manage heart failure patients.
Acorai’s Monitoring system was designated a breakthrough device by the FDA in 2023 and is built upon the patented SAVE Sensor System, a proprietary, non-invasive hardware & machine learning platform.
FinSMEs
22/01/2024